Evidence map›Paper›PMID 42517026›Full record

ArticleHealth science reports2026

Autophagy Modulation in Cancer Therapy: Navigating the Dual Roles to Overcome Chemoresistance.

Md Mohiuddin, Md Al Mamun Ahsan

Abstract read
In one paragraph

Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Md MohiuddinDepartment of Pharmacy Southeast University Dhaka Bangladesh.ORCID https://orcid.org/0000-0002-7313-8655
Md Al Mamun AhsanDepartment of Public Health Daffodil International University, Birulia, Savar Dhaka Bangladesh.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Autophagy is a fundamental cellular recycling mechanism with complex and often opposing roles in cancer, functioning as both a tumor suppressor and a pro-survival mechanism in established tumors. This duality has attracted considerable attention, particularly regarding the therapeutic modulation of autophagy to overcome chemoresistance, a major challenge in cancer treatment. However, the function of autophagy is highly context-dependent and varies with tumor stage, cellular subpopulations, and the tumor microenvironment (TME). Discussion: This perspective examines the multifaceted role of autophagy in cancer, its therapeutic modulation to enhance chemosensitivity, the molecular pathways that regulate autophagy, and the current status of clinical trials with autophagy-targeting agents. We critically discuss the limitations of first-generation autophagy inhibitors, including hydroxychloroquine (HCQ) and chloroquine (CQ). Although these agents show chemosensitizing effects in some preclinical studies and have been evaluated clinically, they lack specificity and may cause off-target toxicities. Particular emphasis is placed on the emerging understanding of selective autophagy pathways, such as mitophagy and ER-phagy, and their context-dependent impact on therapeutic outcomes. We further highlight that successful autophagy-targeted therapy requires a nuanced, precision-based approach that accounts for tumor heterogeneity and microenvironmental influences and integrates advanced drug delivery strategies, including nanomedicine, to achieve spatiotemporal control of autophagy. Conclusion: Targeting autophagy represents a promising yet highly complex strategy for overcoming chemoresistance and requires a transition from global autophagy modulation to selective, context-specific interventions. Future research should focus on developing highly selective autophagy modulators, identifying robust predictive biomarkers, and integrating precision nanomedicine approaches to safely manage autophagy's dual roles and optimize therapeutic outcomes across diverse tumor contexts.

Indexed as

autophagyautophagy inhibitorsautophagy modulationCancer chemosensitizationchemoresistancetumor microenvironment

Identifiers

PMID42517026
PMCPMC13403051

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.